<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[biotechnology and pharmaceutical company Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/biotechnology+and+pharmaceutical+company.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to biotechnology and pharmaceutical company]]></description>
	<s:counts start="0" returned="20" found="87" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Time for Big Pharma to Place Some Bets on Obesity?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003196/time-for-big-pharma-to-place-some-bets-on-obesity/]]></link>
		<description><![CDATA[All three of the leading biotech drugs for obesity remain unpartnered. Orexigen's Phase III program is now complete, and Arena and Vivus should have final Phase III data this quarter...so how long is big pharma going to wait? by Trista Morrison]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 20 Jul 2009 21:20:03 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/orexigen.html"><![CDATA[Orexigen]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/trista+morrison.html"><![CDATA[Trista Morrison]]></category>
	</item>
	<item>
		<title><![CDATA[ASGT: A Reminder That Pharma Doesn't Want to See You Cured]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002439/asgt-a-reminder-that-pharma-doesnt-want-to-see-you-cured/]]></link>
		<description><![CDATA[Pharma and biotech companies are less interested in cures and more interested in medications that require a lifetime of administration, according to scientists at last week's annual meeting of the American Society of Gene Therapy. by Trista Morrison]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 01 Jun 2009 16:31:50 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/trista+morrison.html"><![CDATA[Trista Morrison]]></category>
	</item>
	<item>
		<title><![CDATA[Vanda Vaults From Dog House to Drug Approval]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002022/vanda-vaults-from-dog-stock-to-drug-approval/]]></link>
		<description><![CDATA[IfÂ there was one biotech on every banker's list of cash shells, one dog that could make bankruptcy look like a good option, one name synonymous with snickers and snide comments,Â it was Vanda Pharmaceuticals. Which makes the FDA's approval of Vanda's schizophrenia drug Fanapt iloperidone surprising, to say the least. ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 08 May 2009 13:30:46 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/vanda.html"><![CDATA[Vanda]]></category>
		<category domain="http://resources.bnet.com/topic/fanapt.html"><![CDATA[Fanapt]]></category>
		<category domain="http://resources.bnet.com/topic/street.html"><![CDATA[Street]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/trista+morrison.html"><![CDATA[Trista Morrison]]></category>
	</item>
	<item>
		<title><![CDATA[Pfizer, Vertex Execs Are Victims of Facebook Faker; Forbes, WSJ Also Targeted]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001860/pfizer-vertex-execs-are-victims-of-facebook-faker-forbes-wsj-also-targeted/]]></link>
		<description><![CDATA[Someone is impersonating prominent members of the pharma and biotech world on Facebook, including Vertex Pharmaceuticals chief executive Joshua Boger, a chief science officer at Pfizer and Forbes drug writer Matt Herper. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 29 Apr 2009 07:07:24 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/facebook.html"><![CDATA[Facebook]]></category>
		<category domain="http://resources.bnet.com/topic/wall+street+journal.html"><![CDATA[Wall Street Journal]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/forbes.html"><![CDATA[Forbes]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Maximizing Value In Outsourcing Services]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=1123511]]></link>
		<description><![CDATA[The pharmaceutical industry is, without a doubt, feeling the crunch of skyrocketing costs, lackluster pipelines, and drug safety issues. Clinical professionals need to do more with less, while still maintaining the highest levels of quality. Many companies are choosing Contract Research Organizations CROs as a cost-effective strategy to outsource services...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Sun, 15 Mar 2009 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/genetic+engineering.html"><![CDATA[Genetic Engineering]]></category>
		<category domain="http://resources.bnet.com/topic/outsource.html"><![CDATA[Outsource]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/genetic+engineering+%2526+biotechnology+news.html"><![CDATA[Genetic Engineering & Biotechnology News]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing.html"><![CDATA[Outsourcing]]></category>
		<category domain="http://resources.bnet.com/topic/managed+hosting.html"><![CDATA[Managed Hosting]]></category>
		<category domain="http://resources.bnet.com/topic/it+operations.html"><![CDATA[It Operations]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing+%2526+subcontracting.html"><![CDATA[Outsourcing & Subcontracting]]></category>
	</item>
	<item>
		<title><![CDATA[Drug Makers Gave Lobbyists an Xmas Gift -- Millions More to Lobby Obama Administration]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000547/drug-makers-gave-lobbyists-an-xmas-gift-millions-more-to-lobby-obama-administration/]]></link>
		<description><![CDATA[A New Year will bring a new president, a new FDA chief, many new drug regulations, and, possibly, health insurance reform. Mindful of the ton of major drug brands that will go off-patent in 2009, drug companies have not rested in their lobbying efforts over generics and patent issues. They...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 31 Dec 2008 11:36:49 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[Vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/administration.html"><![CDATA[Administration]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/teva.html"><![CDATA[Teva]]></category>
		<category domain="http://resources.bnet.com/topic/biotech+drug.html"><![CDATA[Biotech Drug]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Roche's DTC Regrets, Novartis and Mylan, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000452/pharma-roundup-roches-dtc-regrets-novartis-and-mylan-and-more/]]></link>
		<description><![CDATA[Roche CEO: DTC ads industry's "worst decision." Novartis and Mylan reach patent deal. Trouble in Biotech-land. AmerisourceBergen and its thrifty CEO. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 02 Dec 2008 17:44:51 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/breast+cancer.html"><![CDATA[Breast Cancer]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Roche Buys Memory, Biotech in NC, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000438/pharma-roundup-roche-buys-memory-biotech-in-nc-and-more/]]></link>
		<description><![CDATA[Roche purchases Memory Pharmaceuticals, North Carolina biotech industry seeks government help, the 5 biggest layoff announcements of 2008. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 26 Nov 2008 17:28:01 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/memory.html"><![CDATA[Memory]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/network+computer.html"><![CDATA[Network Computer]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
	</item>
	<item>
		<title><![CDATA[Half of Small Biotechs Have Less Than One Year of Cash Left]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000404/half-of-small-biotechs-have-less-than-one-year-of-cash-left/]]></link>
		<description><![CDATA[The golden years for biotech startups may be nearing an end, according to an analysis by Jeffries & Co. and San Diego's Xconomy.com. Small biotechs that are publicly traded but not yet profitable are drawing down their cash -- and in some cases running out. Amylin, Somaxon, Arena, and Neurocrine...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 18 Nov 2008 11:21:13 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/san+diego.html"><![CDATA[San Diego]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/san+diego.html"><![CDATA[San Diego]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: NYC Wants Biotech, Amgen Predicts Blockbusters, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000385/pharma-roundup-nyc-wants-biotech-amgen-predicts-blockbusters-and-more/]]></link>
		<description><![CDATA[The city invests in facilities, as Amgen bets big and industry execs are surprisingly blase about cost-cutting. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 12 Nov 2008 18:21:04 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Wyeth Restructures, Anti-Pharma Activist at FDA, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000347/pharma-roundup-wyeth-restructures-anti-pharma-activist-at-fda-and-more/]]></link>
		<description><![CDATA[Wyeth restructures R&D, FDA appointee may cause problems for pharma, BIO launches site to dispute TV show. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 28 Oct 2008 17:48:35 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/cbs+corp..html"><![CDATA[CBS Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CBS</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">CBS,WYE</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Lilly and ImClone Sued, Buyout Spree Still Predicted, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000342/pharma-roundup-lilly-and-imclone-sued-buyout-spree-still-predicted-and-more/]]></link>
		<description><![CDATA[Pension fund sues over Lilly/ImClone deal -- The State-Boston Retirement System of Massachusetts, along with several other ImClone shareholders, claims in the suit that the $70 Lilly paid per share was too low. [Source: Pharmalot]    Pharma buyouts of biotech close? -- Predictions are flying that pharma companies...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 27 Oct 2008 18:46:02 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/philadelphia+inquirer.html"><![CDATA[Philadelphia Inquirer]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/philadelphia+inquirer.html"><![CDATA[Philadelphia Inquirer]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Biotech Market Share Top 5, King and Alpharma, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000291/pharma-roundup-biotech-market-share-top-5-king-and-alpharma-and-more/]]></link>
		<description><![CDATA[Respectable biotech market share for J&J, Novo, Lilly; King extends another offer for Alpharma; Johnson & Johnson sees strong Q3 overall, but not in prescription drug division;   anti-counterfeiting bill includes pharma protection. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 14 Oct 2008 15:23:20 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: AstraZeneca Wins Web Traffic, Genentech Wins "Best Employer," and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000284/pharma-roundup-astrazeneca-wins-web-traffic-genentech-wins-best-employer-and-more/]]></link>
		<description><![CDATA[AstraZeneca's Nexium is most-visited drug website, Genentech voted best place to work, fewer DDMAC warning letters over time, GSK execs talk research. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 10 Oct 2008 14:46:57 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/web.html"><![CDATA[Web]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">AZN,DNA</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Pfizer Re-Slices Organizational Pie, Lilly Dishes Out Zyprexa Settlement, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000268/pharma-roundup-pfizer-re-slices-organizational-pie-lilly-dishes-out-zyprexa-settlement-and-more/]]></link>
		<description><![CDATA[Pfizer reorganizes; Lilly to pay $62 million fine over Zyprexa; biotech losing talent to clean tech; Consumer Reports blacklists 20 drugs for seniors by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 07 Oct 2008 15:11:56 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/layoff.html"><![CDATA[Layoff]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/settlement.html"><![CDATA[Settlement]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/clean+technology.html"><![CDATA[Clean Technology]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Pharma's Deal-Making Frenzy: Lots of Noise, Less Substance]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000212/pharmas-deal-making-frenzy-lots-of-noise-less-substance/]]></link>
		<description><![CDATA[Reading the mainstream press over the last few weeks could give you the strong impression that pharma has entered a phase of deal-making frenzy. Here's how Reuters describes it today:  Big pharmaceutical companies are set to step up the hunt for assets to buy in promising fields like biotechnology,...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 11 Sep 2008 11:34:50 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/mystery+bidder.html"><![CDATA[Mystery Bidder]]></category>
		<category domain="http://resources.bnet.com/topic/imclone.html"><![CDATA[ImClone]]></category>
		<category domain="http://resources.bnet.com/topic/business+structures.html"><![CDATA[Business Structures]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Biotech's New Blockbusters -- Oh, Really?]]></title>
		<link><![CDATA[http://www.bnet.com/5208-14054-0.html?forumID=1&threadID=2698&messageID=13000&start=0]]></link>
		<description><![CDATA[Biotech's New Blockbusters -- Oh, Really?20 to 30 Blockbusters of Biotech Exist NowInnovation in Pharmacology?Beginning in the 1970, biopharmaceuticals were being researched for conceptual production in those places once called academic institutions.  The first biopharmaceutical ever was a synthetic insulin called Humulin made by Genetech in 1982.  Later...]]></description>
		<s:doctype><![CDATA[Discussion threads]]></s:doctype>
		<pubDate>Thu, 10 Jul 2008 17:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biopharma.html"><![CDATA[BioPharma]]></category>
		<category domain="http://resources.bnet.com/topic/biopharmaceutical.html"><![CDATA[biopharmaceutical]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma's Future Leaders -- Or Its Pallbearers]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000105/pharmas-future-leaders-or-its-pallbearers/]]></link>
		<description><![CDATA[Given the challenges facing Big Pharma -- expiring patents, waning drug pipelines, the imploding blockbuster model, and increasing political pressure on its marketing practices -- it's hard not to wonder sometimes just who in their right minds would want to lead its giant but fragile companies over the next decade...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 24 Jun 2008 21:54:43 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/leader.html"><![CDATA[Leader]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/pharmalot.html"><![CDATA[Pharmalot]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">AMGN,GILD,MRK</category>
	</item>
	<item>
		<title><![CDATA[Glaxo Makes Like Ponce de Leon With Sirtris Buy]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100039/glaxo-makes-like-ponce-de-leon-with-sirtris-buy/]]></link>
		<description><![CDATA[You can't fault GlaxoSmithKline for temerity. The U.K. drugmaker's unexpectedly large $720 million bid for Sirtris Pharmaceuticals represents a gutsy bet that the Massachusetts biotech really has a handle on a class of drugs that slow aging. Not that anyone at either company is eager to describe their work that...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 22 Apr 2008 18:24:35 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/sirtris.html"><![CDATA[Sirtris]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
	</item>
	<item>
		<title><![CDATA[Glaxo-Regulus Kicks Off an miRNA Land Grab]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100032/glaxo-regulus-kicks-off-an-mirna-land-grab/]]></link>
		<description><![CDATA[GlaxoSmithKline's willingness to bet up to $600 million on a tiny biotech called Regulus Therapeutics kicks off the latest pharma land grab -- this one for treatments that rely on tiny molecules called microRNAs, or miRNAs for short.    New drug technologies -- or "modalities," as the industry...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 18 Apr 2008 06:34:25 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/mirna.html"><![CDATA[miRNA]]></category>
		<category domain="http://resources.bnet.com/topic/regulus+therapeutics.html"><![CDATA[Regulus Therapeutics]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
	</item>
</channel>
</rss>
